|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-2-28
|
|
pubmed:abstractText |
Osteoclast activation or cartilage and bone destruction are developed in patients with rheumatoid arthritis (RA). The efficacy of etidronate with respect to osteoporosis, inhibition of bone resorption and destruction, and antiinflammation in RA was examined for 72 weeks.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
474-9
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12610804-Aged,
pubmed-meshheading:12610804-Alkaline Phosphatase,
pubmed-meshheading:12610804-Amino Acids,
pubmed-meshheading:12610804-Anti-Inflammatory Agents,
pubmed-meshheading:12610804-Arthritis, Rheumatoid,
pubmed-meshheading:12610804-Bone Density,
pubmed-meshheading:12610804-Bone Resorption,
pubmed-meshheading:12610804-C-Reactive Protein,
pubmed-meshheading:12610804-Etidronic Acid,
pubmed-meshheading:12610804-Female,
pubmed-meshheading:12610804-Humans,
pubmed-meshheading:12610804-Interleukin-6,
pubmed-meshheading:12610804-Male,
pubmed-meshheading:12610804-Middle Aged,
pubmed-meshheading:12610804-Severity of Illness Index
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.
|
|
pubmed:affiliation |
Department of Joint Disease and Rheumatism, Nippon Medical School, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
